We are live on ! Find out more
EWTX icon

Edgewise Therapeutics

31 hedge funds and large institutions have $1.48B invested in Edgewise Therapeutics in 2021 Q1 according to their latest regulatory filings, with 31 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

96.03% more ownership

Funds ownership: 0%96.03% (+96%)

Holders
31
Holders Change
+31
Holders Change %
% of All Funds
0.54%
Holding in Top 10
5
Holding in Top 10 Change
+5
Holding in Top 10 Change %
% of All Funds
0.09%
New
31
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
26
Millennium Management
New York
$1.95M +$1.95M +60,077 New
BlackRock
27
BlackRock
New York
$1.8M +$1.8M +55,485 New
CCM
28
CAAS Capital Management
New York
$975K +$973K +30,000 New
Squarepoint
29
Squarepoint
New York
$656K +$655K +20,185 New
LCM
30
Landscape Capital Management
New Jersey
$290K +$289K +8,923 New
MS
31
Maven Securities
Jersey
$262K +$269K +8,300 New

EWTX Hedge Fund Activity: Q1 2021 in Review

31 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q1 2021, worth a combined $1.48B.

Buyers outnumbered sellers: 31 funds opened new EWTX positions and 0 closed out — a net gain of 31 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $452M.

  • 31 institutional investors held Edgewise Therapeutics (EWTX) as of Q1 2021, up from 0 in Q4 2020.
  • Funds reported $1.48B of Edgewise Therapeutics stock for Q1 2021.
  • 31 funds opened new Edgewise Therapeutics positions in Q1 2021 and 0 closed out, a net change of +31 holders.
  • The largest Edgewise Therapeutics buyer in Q1 2021 was OrbiMed, an estimated $452M added.

Based on aggregated 13F filings for Q1 2021.